Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited. more
Time Frame | CDT | Sector | S&P500 |
---|---|---|---|
1-Week Return | -16.06% | -3.39% | 0.2% |
1-Month Return | -14.15% | -1.92% | 2.72% |
3-Month Return | -43.64% | -10.54% | 7.31% |
6-Month Return | -95.33% | -4.47% | 10.44% |
1-Year Return | -98.71% | 4.06% | 27.53% |
3-Year Return | -99.21% | 0.94% | 30.88% |
Dec '21 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Cost of Revenue | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Gross Profit | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Gross Margin | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Operating Expenses | 3.17M | 3.16M | 5.56M | [{"date":"2021-12-31","value":57.05,"profit":true},{"date":"2022-12-31","value":56.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Income | (3.17M) | (3.16M) | (5.56M) | [{"date":"2021-12-31","value":-317300000,"profit":false},{"date":"2022-12-31","value":-316000000,"profit":false},{"date":"2023-12-31","value":-556200000,"profit":false}] | ||
Total Non-Operating Income/Expense | - | (1.73M) | 4.63M | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-37.26,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | ||
Pre-Tax Income | (3.66M) | (4.89M) | (535.00K) | [{"date":"2021-12-31","value":-365700000,"profit":false},{"date":"2022-12-31","value":-488700000,"profit":false},{"date":"2023-12-31","value":-53500000,"profit":false}] | ||
Income Taxes | 247.44K | 374.86K | (167.90K) | [{"date":"2021-12-31","value":66.01,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-44.79,"profit":false}] | ||
Income After Taxes | - | (5.26M) | (367.11K) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-526186200,"profit":false},{"date":"2023-12-31","value":-36710500,"profit":false}] | ||
Income From Continuous Operations | (3.66M) | (4.89M) | (535.00K) | [{"date":"2021-12-31","value":-365700000,"profit":false},{"date":"2022-12-31","value":-488700000,"profit":false},{"date":"2023-12-31","value":-53500000,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | (3.66M) | (4.89M) | (535.00K) | [{"date":"2021-12-31","value":-365700000,"profit":false},{"date":"2022-12-31","value":-488700000,"profit":false},{"date":"2023-12-31","value":-53500000,"profit":false}] | ||
EPS (Diluted) | - | 0.01 | (0.04) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-409,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
CDT | |
---|---|
Cash Ratio | 0.01 |
Current Ratio | 0.12 |
Quick Ratio | -30.65 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CDT | |
---|---|
ROA (LTM) | -322.02% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CDT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 4.05 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -3.05 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CDT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Conduit Pharmaceuticals Inc. (CDT) share price today is $0.0737
Yes, Indians can buy shares of Conduit Pharmaceuticals Inc. (CDT) on Vested. To buy Conduit Pharmaceuticals Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CDT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Conduit Pharmaceuticals Inc. (CDT) via the Vested app. You can start investing in Conduit Pharmaceuticals Inc. (CDT) with a minimum investment of $1.
You can invest in shares of Conduit Pharmaceuticals Inc. (CDT) via Vested in three simple steps:
The 52-week high price of Conduit Pharmaceuticals Inc. (CDT) is $6.1. The 52-week low price of Conduit Pharmaceuticals Inc. (CDT) is $0.07.
The price-to-earnings (P/E) ratio of Conduit Pharmaceuticals Inc. (CDT) is
The price-to-book (P/B) ratio of Conduit Pharmaceuticals Inc. (CDT) is 0.00
The dividend yield of Conduit Pharmaceuticals Inc. (CDT) is 0.00%
The market capitalization of Conduit Pharmaceuticals Inc. (CDT) is $8.86M
The stock symbol (or ticker) of Conduit Pharmaceuticals Inc. is CDT